Cargando…
Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients Aged 80 Years and Older
The effectiveness of direct oral anticoagulants (DOAC) is non-inferior to vitamin K antagonists (VKA) to treat atrial fibrillation and venous thromboembolism (VTE). In this cross-sectional study, we compared older persons taking DOACs to those taking VKAs. We included ambulatory individuals ≥80 year...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122810/ https://www.ncbi.nlm.nih.gov/pubmed/33922331 http://dx.doi.org/10.3390/ijerph18094443 |
_version_ | 1783692722320703488 |
---|---|
author | Manckoundia, Patrick Nuemi, Gilles Hacquin, Arthur Menu, Didier Rosay, Clémentine Vovelle, Jérémie Nuss, Valentine Baudin-Senegas, Camille Barben, Jérémy Putot, Alain |
author_facet | Manckoundia, Patrick Nuemi, Gilles Hacquin, Arthur Menu, Didier Rosay, Clémentine Vovelle, Jérémie Nuss, Valentine Baudin-Senegas, Camille Barben, Jérémy Putot, Alain |
author_sort | Manckoundia, Patrick |
collection | PubMed |
description | The effectiveness of direct oral anticoagulants (DOAC) is non-inferior to vitamin K antagonists (VKA) to treat atrial fibrillation and venous thromboembolism (VTE). In this cross-sectional study, we compared older persons taking DOACs to those taking VKAs. We included ambulatory individuals ≥80 years, affiliated to Mutualité Sociale Agricole of Burgundy, who were refunded for a medical prescription in September 2017. The demographic conditions, registered chronic diseases (RCD), and number and types of prescribed drugs were compared in the DOAC group and VKA group. Of the 3190 included individuals, 1279 (40%) were prescribed DOACs and 1911 (60%) VKAs. Individuals taking VKAs were older than those taking DOACs (87.11 vs. 86.35 years). In the DOAC group, there were more women (51.92% vs. 48.25%) (p = 0.043), less RCD (89.60% vs. 92.73%) (p = 0.002), less VTE (1.80% vs. 6.59%), less severe heart failure (58.09% vs. 67.87%), less severe hypertension (18.22% vs. 23.60%), less severe kidney diseases (1.49% vs. 3.82%), and fewer drugs per prescription (6.15 vs. 6.66) (p < 0.01 for all). The DOAC group were also less likely to be taking angiotensin receptor blockers (10.79% vs. 13.97%), furosemide (40.81% vs. 49.66%) or digoxin (10.32% vs. 13.66%) than the VKA group (p = 0.009, p < 0.001, and p = 0.005). DOACs were less prescribed than VKAs. Individuals taking VKAs were older and had more severe comorbidities and more drugs per prescription than those taking DOACs. |
format | Online Article Text |
id | pubmed-8122810 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-81228102021-05-16 Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients Aged 80 Years and Older Manckoundia, Patrick Nuemi, Gilles Hacquin, Arthur Menu, Didier Rosay, Clémentine Vovelle, Jérémie Nuss, Valentine Baudin-Senegas, Camille Barben, Jérémy Putot, Alain Int J Environ Res Public Health Article The effectiveness of direct oral anticoagulants (DOAC) is non-inferior to vitamin K antagonists (VKA) to treat atrial fibrillation and venous thromboembolism (VTE). In this cross-sectional study, we compared older persons taking DOACs to those taking VKAs. We included ambulatory individuals ≥80 years, affiliated to Mutualité Sociale Agricole of Burgundy, who were refunded for a medical prescription in September 2017. The demographic conditions, registered chronic diseases (RCD), and number and types of prescribed drugs were compared in the DOAC group and VKA group. Of the 3190 included individuals, 1279 (40%) were prescribed DOACs and 1911 (60%) VKAs. Individuals taking VKAs were older than those taking DOACs (87.11 vs. 86.35 years). In the DOAC group, there were more women (51.92% vs. 48.25%) (p = 0.043), less RCD (89.60% vs. 92.73%) (p = 0.002), less VTE (1.80% vs. 6.59%), less severe heart failure (58.09% vs. 67.87%), less severe hypertension (18.22% vs. 23.60%), less severe kidney diseases (1.49% vs. 3.82%), and fewer drugs per prescription (6.15 vs. 6.66) (p < 0.01 for all). The DOAC group were also less likely to be taking angiotensin receptor blockers (10.79% vs. 13.97%), furosemide (40.81% vs. 49.66%) or digoxin (10.32% vs. 13.66%) than the VKA group (p = 0.009, p < 0.001, and p = 0.005). DOACs were less prescribed than VKAs. Individuals taking VKAs were older and had more severe comorbidities and more drugs per prescription than those taking DOACs. MDPI 2021-04-22 /pmc/articles/PMC8122810/ /pubmed/33922331 http://dx.doi.org/10.3390/ijerph18094443 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Manckoundia, Patrick Nuemi, Gilles Hacquin, Arthur Menu, Didier Rosay, Clémentine Vovelle, Jérémie Nuss, Valentine Baudin-Senegas, Camille Barben, Jérémy Putot, Alain Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients Aged 80 Years and Older |
title | Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients Aged 80 Years and Older |
title_full | Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients Aged 80 Years and Older |
title_fullStr | Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients Aged 80 Years and Older |
title_full_unstemmed | Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients Aged 80 Years and Older |
title_short | Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients Aged 80 Years and Older |
title_sort | direct oral anticoagulants versus vitamin k antagonists in patients aged 80 years and older |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122810/ https://www.ncbi.nlm.nih.gov/pubmed/33922331 http://dx.doi.org/10.3390/ijerph18094443 |
work_keys_str_mv | AT manckoundiapatrick directoralanticoagulantsversusvitaminkantagonistsinpatientsaged80yearsandolder AT nuemigilles directoralanticoagulantsversusvitaminkantagonistsinpatientsaged80yearsandolder AT hacquinarthur directoralanticoagulantsversusvitaminkantagonistsinpatientsaged80yearsandolder AT menudidier directoralanticoagulantsversusvitaminkantagonistsinpatientsaged80yearsandolder AT rosayclementine directoralanticoagulantsversusvitaminkantagonistsinpatientsaged80yearsandolder AT vovellejeremie directoralanticoagulantsversusvitaminkantagonistsinpatientsaged80yearsandolder AT nussvalentine directoralanticoagulantsversusvitaminkantagonistsinpatientsaged80yearsandolder AT baudinsenegascamille directoralanticoagulantsversusvitaminkantagonistsinpatientsaged80yearsandolder AT barbenjeremy directoralanticoagulantsversusvitaminkantagonistsinpatientsaged80yearsandolder AT putotalain directoralanticoagulantsversusvitaminkantagonistsinpatientsaged80yearsandolder |